Literature DB >> 6339094

High-dose melphalan and autologous bone marrow transplant for relapsed acute leukaemia.

D Maraninchi, M Abecasis, J A Gastaut, G Sebahoun, J Y Cahn, P Hervé, G Novakovitch, Y Carcassonne.   

Abstract

Seven patients with relapsed acute leukaemia were treated with high-dose melphalan (HDM) followed by the infusion of autologous cryopreserved remission marrow. Toxicity was minimal and all seven patients had a complete response. Four patients are still in unmaintained remission at 14, 13, 10, and 3 months, the first two having received a second course of HDM to consolidate the result. The role of HDM as a form of intensification therapy for patients with acute myeloid leukaemia in first remission should be investigated.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6339094     DOI： 10.1007/bf00446220

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  6 in total

1.  Vinblastine, 5-azacytidine, and VP-16-213 therapy for previously treated patients with acute nonlymphocytic leukemia.

Authors:  D A Van Echo; K M Lichtenfeld; P H Wiernik
Journal:  Cancer Treat Rep       Date:  1977-11

2.  High dose cytosine arabinoside (HDARAC) in refractory acute leukemia.

Authors:  S A Rudnick; E C Cadman; R L Capizzi; R T Skeel; J R Bertino; S McIntosh
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

3.  Autologous bone-marrow transplantation in relapsed adult acute leukaemia.

Authors:  K A Dicke; A Zander; G Spitzer; D S Verma; L Peters; L Vellekoop; K B McCredie; J Hester
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

Review 4.  5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.

Authors:  D D Von Hoff; M Slavik; F M Muggia
Journal:  Ann Intern Med       Date:  1976-08       Impact factor: 25.391

5.  4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.

Authors:  S S Legha; M J Keating; A R Zander; K B McCredie; G P Bodey; E J Freireich
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391

6.  Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.

Authors:  T J McElwain; D W Hedley; G Burton; H M Clink; M Y Gordon; M Jarman; C A Juttner; J L Millar; R A Milsted; G Prentice; I E Smith; D Spence; M Woods
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640
  6 in total
  6 in total

1.  Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation.

Authors:  Masatoshi Sakurai; Takehiko Mori; Jun Kato; Yuya Koda; Taku Kikuchi; Sumiko Kohashi; Masuho Saburi; Takaaki Toyama; Yoshinobu Aisa; Tomonori Nakazato; Noriko Beppu; Soichiro Tsuda; Naoyuki Shigematsu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2014-03-12       Impact factor: 2.490

2.  Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.

Authors:  M H Gaspard; D Maraninchi; A M Stoppa; J A Gastaut; G Michel; N Tubiana; D Blaise; G Novakovitch; J F Rossi; P J Weiller
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide). First clinical results.

Authors:  P Hervé; J Y Cahn; E Plouvier; M Flesch; E Tamayo; R Leconte des Floris; A Peters
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation.

Authors:  O Hartmann; C Kalifa; E Benhamou; C Patte; F Flamant; C Jullien; F Beaujean; J Lemerle
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Phase-I-II study of high-dose melphalan and autologous marrow transplantation in adult patients with poor-risk non-Hodgkin's lymphomas.

Authors:  B Mascret; D Maraninchi; J A Gastaut; D Baume; G Sebahoun; C Lejeune; G Novakovitch; D Sainty; N Horchowski; N Tubiana
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.

Authors:  B A Robinson; R D Clutterbuck; J L Millar; T J McElwain
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.